 Outlook Therapeutics Inc NASDAQ: OTLK stock is trading higher in premarket session in reaction to positive top-line results from Phase 3 NORSE TWO trial evaluating ONS-5010 LYTENAVA bevacizumab for neovascular age-related macular degeneration wet AMD. The primary endpoint for the study was the proportion of patients who gain at least 15 letters in the best-corrected visual acuity BCVA at 11 months. 